Price-to-earnings: BT vs RX

Profitable biotech's mean P/E has fallen 13% to 12.9 since 3Q09, while big pharma's multiple is off 5% to 10.1. Biotech's multiple thus is down to 1.3 times big pharma's at the end of 3Q10 vs. 1.4 tim...